Scholarlink

Background <p>Small cell lung cancer (SCLC), an aggressive neuroendocrine malignancy, exhibits high intertumoral heterogeneity and limited treatment options. Immune checkpoint inhibitors (ICIs) provide only modest benefits for SCLC, underscoring the need for clinically actionable phenotypes.</p> Methods <p>Consensus clustering of bulk transcriptomic data identified SCLC molecular phenotypes. Bulk and single-cell RNA sequencing (scRNA-seq) revealed their molecular and immune characteristics, as well as tumor microenvironment interactions. Survival benefits of ICIs were assessed in 41 newly collected extensive-stage SCLC (ES-SCLC) patients treated with chemotherapy plus ICIs, integrated with a public dataset.</p> Results <p>We identified three distinct SCLC phenotypes, termed proliferative, iNotch, and infiltrated phenotypes, as they were characterized by high proliferation, inhibitory Notch signaling, and immune-rich microenvironments, respectively. These phenotypes were reproducible across three bulk independent datasets. Further intercellular communication analysis of scRNA-seq data revealed a subset with high <i>ANXA1</i> expression in the infiltrated phenotype suppressed CD8<sup>+</sup> T cells via M2 macrophage polarization. Survival analyses showed that only <i>ANXA1</i><sup><i>Low</i></sup> infiltrated patients derived significant survival benefit from chemotherapy plus ICIs.</p> Conclusions <p>This study identified three distinct SCLC phenotypes with unique therapeutic vulnerabilities. An <i>ANXA1</i><sup><i>High</i></sup> subset within the immune-rich infiltrated phenotype showed ICI resistance, offering new strategies to enhance ICI efficacy.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular phenotypes stratify small cell lung cancer for targeted therapy and immunotherapy

  • 期刊论文

  • 发表日期：

    2026年4月3日

查看全文
  • Juxuan Zhang,
  • Yiyan Liu,
  • Hengrui Yuan,
  • Ning Zhan,
  • Jiaxing Deng,
  • Lefan Tang,
  • Xin Li,
  • Yixin Liu,
  • Wenyuan Zhao,
  • Shilong Liu,
  • Lishuang Qi

摘要

Background

Small cell lung cancer (SCLC), an aggressive neuroendocrine malignancy, exhibits high intertumoral heterogeneity and limited treatment options. Immune checkpoint inhibitors (ICIs) provide only modest benefits for SCLC, underscoring the need for clinically actionable phenotypes.

Methods

Consensus clustering of bulk transcriptomic data identified SCLC molecular phenotypes. Bulk and single-cell RNA sequencing (scRNA-seq) revealed their molecular and immune characteristics, as well as tumor microenvironment interactions. Survival benefits of ICIs were assessed in 41 newly collected extensive-stage SCLC (ES-SCLC) patients treated with chemotherapy plus ICIs, integrated with a public dataset.

Results

We identified three distinct SCLC phenotypes, termed proliferative, iNotch, and infiltrated phenotypes, as they were characterized by high proliferation, inhibitory Notch signaling, and immune-rich microenvironments, respectively. These phenotypes were reproducible across three bulk independent datasets. Further intercellular communication analysis of scRNA-seq data revealed a subset with high ANXA1 expression in the infiltrated phenotype suppressed CD8+ T cells via M2 macrophage polarization. Survival analyses showed that only ANXA1Low infiltrated patients derived significant survival benefit from chemotherapy plus ICIs.

Conclusions

This study identified three distinct SCLC phenotypes with unique therapeutic vulnerabilities. An ANXA1High subset within the immune-rich infiltrated phenotype showed ICI resistance, offering new strategies to enhance ICI efficacy.